Form 4 for MAIA MAIA Biotechnology, Inc.
Accepted 2023-01-06 00:00:00 ET · period of report 2023-01-04 · accession 0001127602-23-001010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-06 | 2023-01-04 | MAIA | Vitoc Vlad | CEO, Dir, 10% | P - Purchase | $3.68 | +1,266 | 793.1K | +0.2% | +$4,659 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-04 | P | A | 1,266 | $3.68 | 793,121 | D | — | — | (F2) The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.59 to $3.75, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. (F1) The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Vitoc that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. |